Seres Therapeutics, Inc. (NASDAQ:MCRB) has received an average recommendation of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.83.
Separately, Zacks Investment Research upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 16th.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MCRB. Teacher Retirement System of Texas purchased a new position in Seres Therapeutics during the third quarter valued at $77,000. BNP Paribas Arbitrage SA lifted its position in Seres Therapeutics by 377.9% during the third quarter. BNP Paribas Arbitrage SA now owns 12,527 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 9,906 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Seres Therapeutics by 559.3% during the second quarter. Nisa Investment Advisors LLC now owns 3,890 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 3,300 shares in the last quarter. FORA Capital LLC purchased a new position in Seres Therapeutics during the second quarter valued at $94,000. Finally, Royal Bank of Canada lifted its position in Seres Therapeutics by 90.3% during the second quarter. Royal Bank of Canada now owns 4,765 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,261 shares in the last quarter. Institutional investors own 83.25% of the company’s stock.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Wednesday, November 10th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $1.19. The firm had revenue of $126.73 million for the quarter, compared to the consensus estimate of $7.12 million. Seres Therapeutics had a negative return on equity of 22.73% and a negative net margin of 21.79%. During the same period last year, the business posted ($0.36) EPS. On average, equities analysts forecast that Seres Therapeutics will post -0.63 earnings per share for the current year.
About Seres Therapeutics
Seres Therapeutics, Inc engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Featured Article: How the Dogs of the Dow Strategy Works
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.